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zero, and 2-4 concomitant vaccines, respectively. About 49% of the reports indi-
cated that patients were on concurrentmedications at the time of vaccination, yet;
only 12% of the reports stated that the patients were having coexisting illnesses at
vaccination time. Compared to other vaccines, FLU and MNQ vaccines showed
significantly higher PRR values (10.5, 95%CI 9.4-11.8), (4.7, 95%CI 3.4-6.6).
CONCLUSIONS: It can be postulated that some vaccines are associated with GBS,
especially FLU and MNQ vaccines; underscoring the importance of monitoring pa-
tients for postvaccination signs and symptoms of GBS. While healthcare profes-
sionals are expected to promote vaccination, they should also continue to report
vaccine-associated adverse events to vaccine safety monitoring systems, e.g.
VAERS.
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OBJECTIVES: MRSA skin infections are associated with high morbidity and cost.
Little is known about real-world daptomycin effectiveness in relevant subpopula-
tions. We evaluated outcomes including time to response, duration of antibiotic
therapy, and antibiotic-related hospital length of stay (AR-LOS) in subpopulations
of patients with MRSA skin infections treated with daptomycin. METHODS: Pa-
tients with MRSA skin infections were identified in a retrospective, multicenter,
observational registry describing safety and real-world effectiveness of patients
treated with daptomycin (Cubicin Outcomes Registry and Experience; CORE®). In-
vestigators assessed patient outcome at the end of daptomycin therapy. Subpopu-
lations of interest included those with reduced vancomycin susceptibility (MIC
2mcg/mL), the elderly, diabetics, and those with renal dysfunction. RESULTS: A
total of 137 patients were identified: 53% male, 33% 65yo, 31% diabetic, 6% CrCL
30ml/min. Of patients with vancomycin MICs, 14% were2. Median daptomycin
dose was 6mg/kg; 82% had prior antibiotics (66% of which was vancomycin). Suc-
cess occurred in 94% overall, and was 100% in first-line daptomycin, 93% as second
line. Time to clinical response ranged from 2-4 days with a median of 3 days for
both first and second-line therapy. Median AR-LOS tended to be greater among
subpopulations: those with vancomycin MIC2 [5 vs. 4 days],65 yo [6 vs. 5 days],
diabetics [6 vs. 4 days], and those with CrCL 30 [8 vs. 5 days], compared to those
without each respective condition. Total treatment duration (inpatient and outpa-
tient days) ranged from 7-13 days, depending on clinical subgroup. 11/137 patients
(8.3%) had AEs possibly related to daptomycin; discontinuation due to AEwas 5.8%.
CONCLUSIONS:This evaluation of relevant patient populations providesmeaning-
ful information about real-world effectiveness of daptomycin-treated MRSA skin
infections. AR-LOSwas longer in evaluated subgroups, particularly thosewith CrCL
30ml/min. Additional real-world evaluations, including comparative effective-
ness studies are warranted to further evaluate relevant outcomes in various sub-
populations with MRSA skin infections.
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OBJECTIVES: In diabetes mellitus patients, infected diabetic foot represents 20% of
hospitalizations. In order tominimize health services cost its important to evaluate
which antimicrobial agent could be the best option. The aim of this study was to
conduct a meta-analysis of randomized clinical trials (RCTs) to determine effec-
tiveness and safety of linezolid in the treatment of infected diabetic foot in com-
parisonwith other antimicrobial agents.METHODS:All meta-analysis estimations
were performedwith RCTs based on trials enrolling patientswithmild tomoderate
diabetic foot infections treated with one antimicrobial agent. Effectiveness was
assessed through clinical efficacy (cure/healing); safety and microbiological end-
point indicators. RCTs were searched in December 2009 in Medline, EMBASE, and
the Cochrane Collaboration. Two independent reviewers identified abstracts, se-
lected full articles, and extracted the data. Odds ratios (OR) and weighted mean
differences were calculated. Random effects models were employed in the analy-
seswith RevMan v.5.0 software.RESULTS: 1,528 studieswere reviewed and 19 trials
were finally selected. 13/19 RCTs assessed patients with diabetes mellitus and 6/19
patients with soft tissue infections. Regarding clinical results: linezolid was as
effective as ciproflaxin, ofloxacin and ertapenem; although with higher clinical
efficacy compared to piperacillin/tazobactam (OR 0.52; IC95% 0.340.77 p0.001),
ampicillin/sulbactam (OR 0.40; CI95% 0.270.61 p0.001) and daptomicin (OR 0.45;
IC95% 0.22-0.90 p0.02). Regarding microbiological efficacy, similar results were
estimated (Staph. aureus eradication); however, ertapenem showed a better result
(OR 2.60; CI95% 1.11–6.07 p0.03) than linezolid. Nevertheless, linezolid exhibited
superiority against oxiflacin (OR 0.36; CI95% 0.20-0.65, p0.0006). Frequency of
adverse events was similar in all RCTs. CONCLUSIONS: Currently, little published
evidence exists to define which antimicrobial agent would be the optimum drug
for mild to moderate infected diabetic foot patients. Though, linezolid demon-
strated to be an effective and safe treatment using clinical and microbiological
endpoints.
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OBJECTIVES: In patients with HIV-1, the reduction in RNA copies associated to
treatment has shown a better survival rate. The Highly Active Antiretroviral Ther-
apy (HAART) is the recommended treatment for those patients. As a chronic dis-
ease, the adherence to treatment and adverse effects plays a mayor role. The
objective was to evaluate the efficacy and safety of the combination Efavirenz,
Tenofovir and Emtricitabine (EFV/TDF/FTC) administred once daily compared to
the available treatment combinations in Mexico. METHODS: We conducted a
systematic review using the Cochrane guidelines of randomized clinical trials in
PubMed, EMBASE, LILACS AND Artemisa to compare EFV/TDF/FTC, TDF/
FTCATV/r, TDF/FTCLPV/r, TDF/FTCSQV/r, TDF/FTCFPV/r, ABC/3TCEFV,
ABC/3TCLPV/r, ZDV/3TC/EFV, ZDV/3TCLPV/r in naïve adult patients with
HIV-1 infection. The main outcome variables were RNA HIV-1 copies less than
50/mm3 at 48 and 96 weeks, and grade 2-4 adverse effects at 48 weeks. We used
a random model effects for the pooled analysis. RESULTS: We included 13 arti-
cles, 9 at 48weeks and 4 at 96weeks. The armswere grouped by the three elements
of HAART. The combination EFV/TDF/FTC was the most frequently used (4 and 2
studies at 48 and 96weeks). At 48 and 96weeks the pooled probabilities to have50
RNA copies/ml for EFV/TDF/FTC were 0.784 (CI95%:0.736-0.825; n962) and 0.734
(0.601-0.835; n514); TDF/FTCLPV/r 0.694(0.611-0.766; n958) and 0.633(0.528-
0.726; n788); TDF/FTCATV/r 0.848(0.652-0.943; n488) and 0.743(0.700-0.782;
n440) respectively. The 2-4 grade adverse events rates at 48 weeks were for EFV/
TDF/FTC 0.225(0.074-0.513; n1129); for ABC/3TCEFV 0.316(0.279-0.354; n589); and
for ZDV/3TC/EFV 0.634(0.573-0.691; n254). At 48 weeks the discontinuation rate for
EFV/TDF/FTCwas 0.051(n536); TDF/FTCLPV/r 0.071(n170); and for ZDV/3TCEFV
0.079(n349); the lowestwas TDF/FTCSQV 0.028(n176).CONCLUSIONS: The com-
bination EFV/TDF/FTC is themost studied combination and is clinically effective at
48 and 96 weeks, with good safety profile. The administration once a day improves
the adherence to treatment.
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OBJECTIVES:The global prevalence of hepatitis C virus (HCV) infection is estimated
at over 300million persons. Despite stable prevalence, the economic burden in the
United States (US) is projected to double over the next decade. Less is known,
however, for the rest of the Americas. These epidemiologic and economic data are
critical for decision-makers to project the impacts of HCV treatments. The objec-
tive of this study was to synthesize literature-based estimates of the prevalence
and economic burden of HCV fromCanada,Mexico, Brazil, Argentina, Peru, Colom-
bia, and Venezuela.METHODS: A systematic review was conducted in September
2010 to determine the a) prevalence, and b) resultant economic burden, of HCV.
Two independent reviewers extracted data from articles meeting the inclusion
criteria: from EMBASE, Medline, or the Cochrane databases; focusing on general
population estimates from the target countries; and published since the year 2000.
RESULTS: The search strategy identified 280 abstracts; eight provided general pop-
ulation prevalence estimates. In Brazil, the prevalencewas estimated at 1.4% in Sao
Paulo, and 3.6% in the state of Para. Canadian national surveillance programs es-
timated HCV prevalence at 0.8%; with provincial estimates from 1.3% to 2.0%. Mex-
ican estimates ranged from 0.7% to 2.0%; the national health survey reported a
prevalence of 1.4%. No prevalence estimates were identified for the remaining
countries. Only one study (from Canada) assessed the overall economic burden.
Despite a predicted 14% decrease in prevalence, HCV-related costs were projected
to increase by over 50%, to 158 million dollars annually by 2040. CONCLUSIONS:
HCV prevalence estimates varied from 0.8% to 3.6%, from general population based
studies from Canada, Mexico, and Brazil. Canadian data suggest the economic
burden of HCV is large, and increasing. While these data are useful for decision-
makers, the paucity of data for South America highlights a substantial knowledge
gap.
PIN6
TRENDS OF HEPATITIS A INCIDENCE FROM 2005 TO 2008
Eisenberg D1, Changolkar AK2, Misurski DA2
1HealthCore, Inc., Wilmington, DE, USA, 2GlaxoSmithKline, Philadelphia, PA, USA
In 1996 theUSAdvisoryCommittee on ImmunizationPractices recommendedadmin-
istration of hepatitis A vaccine for those at risk of infection. In 2005, the recommen-
dation was extended to all children and at risk adults. Comprehensive data on hepa-
titis A incidence in amanaged care population has not been evaluated. OBJECTIVES:
To evaluate the incidence of hepatitis A in amanaged care population from 2005 to
2008. METHODS: This was an observational, retrospective cohort study utilizing
medical and pharmacy claims data from January 1, 2005 through December 31,
2008 from the HealthCore Integrated Research Database (HIRDSM). The index date
was defined as date of first diagnostic claim for hepatitis Awithin the intake period.
Patients included were at least 18 years old and had continuous eligibility for at
least 12 months prior to and after index date. RESULTS: A total of 7674 patients
were diagnosed with hepatitis A (51.1% male). Annual incidence was similar for
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